C
Christoph Hoeller
Researcher at Medical University of Vienna
Publications - 85
Citations - 6958
Christoph Hoeller is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Melanoma & Ipilimumab. The author has an hindex of 32, co-authored 85 publications receiving 5299 citations. Previous affiliations of Christoph Hoeller include University of Vienna & Wistar Institute.
Papers
More filters
Journal ArticleDOI
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S. Weber,Sandra P. D'Angelo,David R. Minor,F. Stephen Hodi,Ralf Gutzmer,Bart Neyns,Christoph Hoeller,Nikhil I. Khushalani,Wilson H. Miller,Christopher D. Lao,Gerald P. Linette,Luc Thomas,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Michele Maio,Mario Sznol,Paolo A. Ascierto,Peter Mohr,Bartosz Chmielowski,Alan H. Bryce,Inge Marie Svane,Jean-Jacques Grob,Angela M. Krackhardt,Christine Horak,Alexandre Lambert,Arvin Yang,James Larkin +27 more
TL;DR: Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab or ipilicumab and a BRAF inhibitor.
Journal ArticleDOI
Chemosensitisation of malignant melanoma by BCL2 antisense therapy
Burkhard Jansen,V. Wacheck,E. Heere-Ress,H. Schlagbauer-Wadl,Christoph Hoeller,T. Lucas,M. Hoermann,U. Hollenstein,Klaus Wolff,H Pehamberger +9 more
TL;DR: Systemic administration of augmerosen downregulated the target BCL2 protein in metastatic cancer, combined with standard anticancer therapy, offers a new approach to the treatment of patients with resistant neoplasms.
Journal ArticleDOI
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin,David R. Minor,Sandra P. D'Angelo,Bart Neyns,Michael Smylie,Wilson H. Miller,Ralf Gutzmer,Gerald P. Linette,Bartosz Chmielowski,Christopher D. Lao,Paul Lorigan,Kenneth F. Grossmann,Jessica C. Hassel,Mario Sznol,Adil Daud,Jeffrey A. Sosman,Nikhil I. Khushalani,Dirk Schadendorf,Christoph Hoeller,Dana Walker,George Kong,Christine Horak,Jeffrey S. Weber,Jeffrey S. Weber +23 more
TL;DR: The coprimary overall survival (OS) end point of CheckMate 037 is reported, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma.
Journal ArticleDOI
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A. Ascierto,Michele Del Vecchio,Caroline Robert,Andrzej Mackiewicz,Vanna Chiarion-Sileni,Ana Arance,Céleste Lebbé,Lars Bastholt,Omid Hamid,Piotr Rutkowski,Catriona M. McNeil,Claus Garbe,Carmen Loquai,Brigitte Dréno,Luc Thomas,Jean-Jacques Grob,Gabriella Liszkay,Marta Nyakas,Ralf Gutzmer,Joanna Pikiel,Florent Grange,Christoph Hoeller,Virginia Ferraresi,Michael Smylie,Dirk Schadendorf,Laurent Mortier,Inge Marie Svane,Delphine Hennicken,Anila Qureshi,Michele Maio +29 more
TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.
Journal ArticleDOI
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.
Karoline Kollmann,Gerwin Heller,Christine Schneckenleithner,Wolfgang Warsch,Ruth Scheicher,Rene G. Ott,Markus Schäfer,Sabine Fajmann,Michaela Schlederer,Ana-Iris Schiefer,Ursula Reichart,Matthias Mayerhofer,Christoph Hoeller,Sabine Zöchbauer-Müller,Dontscho Kerjaschki,Christoph Bock,Lukas Kenner,Gerald Hoefler,Michael Freissmuth,Anthony R. Green,Richard Moriggl,Meinrad Busslinger,Marcos Malumbres,Veronika Sexl +23 more
TL;DR: The finding that CDK6 connects cell-cycle progression to angiogenesis confirmsCDK6’s central role in hematopoietic malignancies and could underlie the selection pressure to upregulate CDK 6 and silence p16INK4a.